Dr Reddys Laboratories
Recent Highlights
All Stories for Dr Reddys Laboratories
Dr Reddy's Laboratories launches Sputnik V COVID-19 vaccine in India at Rs 995 per dose
•The Hyderabad-based pharma company said that the first dose of the vaccine was administered to a beneficiary as part of a 'limited pilot'
Daily cases jump to 18,855 just days after 8-month low; Centre asks states to inoculate frontline workers from Feb
Fp Staff •Dr Reddy's Laboratories on Friday said it expects Russia's COVID-19 vaccine Sputnik V to be launched in India through Emergency Use Authorisation by March this year
Dr Reddy's Laboratories reports Rs 570 cr loss for Q3 on impairment of generic Nuvaring drug; revenue up 14%
•Dr Reddy's Laboratories Limited's suffered nearly Rs 570 crore loss for the quarter ended 31 December against Rs 485 crore profit after tax during the corresponding period of FY19, the company said on Monday
Dr Reddys PAT more than doubles to Rs 1,093 crore in September quarter; revenue jumps 26% to Rs 4,801 cr
•Dr Reddys also had an income tax benefit of Rs 326 crore during the quarter.
Dr Reddy's Laboratories net profit rises 45% to Rs 663 cr in June quarter; revenue up 3.3%
•Dr Reddy's Laboratories on Monday posted a 45.31 percent rise in consolidated net profit at Rs 662.8 crore for the June quarter
AstraZeneca moves US court against Dr Reddy's Laboratories on generic drug Brilinta
•Pharma major AstraZeneca has filed a petition in a USA court alleging Dr Reddy's Laboratories Limited is attempting to come out with a generic version of its patented blockbuster drug Brilinta (Ticagrelor) in the US market before the expiration of a patent of the drug (276)
Dr Reddy's Laboratories' Q4 consolidated net profit jump 44% at Rs 434 cr; revenue up 14%
•Dr Reddy's Laboratories Limiteds consolidated profit after tax for the quarter-ended 31 March, 2019 was up by 44 percent at Rs 434.4 crore against Rs 302.2 crore in the third quarter of FY 18, a senior official of the city-based drug maker said on Friday
Dr Reddy's PAT surges 45% at Rs 485 cr in Q3; revenues from North America decline 8% to Rs 1,480 cr
•Revenues from India grew by 10 percent to Rs 670 crore driven by volume traction and new products. Europe sales was up by one per cent to Rs 200 crore, the official said.
Dr Reddy's Laboratories, private equity major KKR appoint former Axis Bank chief Shikha Sharma in advisory role
•Shikha Sharma's stint was curtailed by the RBI for unspecified reasons and the third largest private sector lender is now headed by Amitabh Chaudhry.
Dr Reddy's Laboratories' Q2 net profit soars 77% to Rs 504 cr; revenue up 7% to Rs 3,798 cr
•Commenting on the results, Dr Reddy's Lab's co-chairman and CEO, G V Prasad said, "I am encouraged by our performance and progress in the second quarter. Our continuous focus on execution, operational efficiency and cost optimization are showing results.